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Abstract 23 
Group B streptococcus (GBS) capsular serotype is a major determinant of virulence, 24 
and affects potential vaccine coverage. Here we report a whole genome sequencing-25 
based method for GBS serotype assignment. This shows high agreement 26 
(kappa=0.92) with conventional methods, and increased serotype assignment 27 
(100%) to all ten capsular types. 28 
 29 
Main text 30 
Streptococcus agalactiae, or Group B Streptococcus (GBS), is an important 31 
pathogen in neonates (1-3), with early infection acquired from the maternal genito-32 
urinary tract (4). In addition, GBS is now recognised as an increasingly important 33 
pathogen in high-income regions in immunosuppressed and elderly individuals (5, 6).  34 
GBS expresses a capsular polysaccharide, which is involved in virulence and 35 
immune evasion. Ten different variants, or serotypes, have been described (Ia, Ib, II, 36 
III, IV, V VI, VII, VIII and IX), which differ in their disease-causing ability. Conjugate 37 
vaccines targeting the most common disease-causing serotypes are currently in 38 
development (7). Establishing vaccine serotype coverage is important, as is 39 
surveillance post-introduction to monitor for potential serotype replacement, as has 40 
been seen following the introduction of other conjugate vaccines (8).  41 
Current methods for GBS serotype allocation rely on latex agglutination assays or 42 
PCR (9). Recent advances in whole genome sequencing (WGS) have enabled the 43 
development of approaches that can be used in place of traditional microbiological 44 
methods, such as strain typing and antibiotic susceptibility profiling (10-12). A major 45 
advantage of this approach is that the cost of sequencing can be mitigated by the 46 
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ability to use the same data to generate multiple outputs. Given the decreasing cost 47 
of WGS (13), and the ongoing increase in WGS data generation, we sought to 48 
establish and validate a WGS-based method for GBS capsular typing.  49 
We developed an algorithm for serotype assignment on the basis of sequence 50 
similarity between a given de novo assembly and capsular gene sequences of the 51 
ten GBS serotypes. For nine serotypes, published sequences were used as 52 
references (Table 1), while for serotype IX, only a partial capsular locus sequence 53 
has been published (14). A suitable reference for the full capsular locus region was 54 
therefore determined by WGS of a serotype IX isolate obtained from the Statens 55 
Serum Institute, Denmark.   56 
To assign serotype for a given isolate, a BLAST database was generated from the 57 
de novo assembly and queried with the variable region of the capsular locus 58 
sequence for each serotype (cpsG-cpsK for serotypes Ia-VII and IX, cpsR-cpsK for 59 
serotype VIII) using BLASTn with an evalue threshold of 1e-100 and otherwise 60 
default parameters. A serotype was considered as correct if it showed ≥95% 61 
sequence identity over ≥90% of the sequence length. These thresholds were chosen 62 
on the basis of being stringent enough to provide differentiation between the various 63 
reference sequences, while maximising serotype allocation on an initial test set of 64 
publicly available GBS WGS data, where serotype information was not available (so 65 
we had no way of knowing whether the assigned serotypes were in fact correct).  66 
This sequence-based method for serotype allocation was validated using WGS on a 67 
set of 223 colonising or invasive human isolates from Canada, Latin America, 68 
Singapore, UK, USA, and Thailand, for which serotype had previously been 69 
determined using conventional latex agglutination assays, with PCR used to confirm 70 
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weak positives or negatives in a subset (15-17). For two rare serotypes (Serotype 71 
VIII and IX), one isolate of each was obtained from the Statens Serum Institute, 72 
Denmark. GBS isolates stored at -80°C were sub-cultured on Columbia blood agar 73 
for 24-48 hours, followed by DNA extraction from a single colony using a commercial 74 
kit (QuickGene, Fujifilm, Tokyo, Japan). High throughput sequencing was 75 
undertaken at the Wellcome Trust Centre for Human Genetics (Oxford University, 76 
UK) using the Illumina HiSeq2500 platform, generating 150 base paired-end reads. 77 
De novo assembly was performed using Velvet and VelvetOptimiser (18, 19). 78 
Agreement between serotype allocations was tested with the Kappa statistic. 79 
High quality sequence data were obtained for all 223 GBS isolates (median read 80 
number: 2,975,508, range: 1,798,744-13,073,718; median contig number: 46, range 81 
16-106; median assembly length: 2.05 Mb, range: 1.94-2.22 Mb). Each isolate was 82 
allocated to a single serotype using the WGS data (Table 2). Three isolates that did 83 
not have a capsular type assigned by latex agglutination methods had serotypes Ib, 84 
VI and VIII assigned. For all previously serotyped GBS isolates with a known capsule 85 
type, the kappa statistic (0.92) indicated very high agreement between WGS-86 
predicted and conventional serotype. There were nine discordant isolates. In each 87 
case there was strong support for the sequence-allocated serotype, with >98% 88 
sequence identity over 100% of the reference length in all nine cases (Figure 1). 89 
Across all isolates, differences in relatedness between the capsular locus sequences 90 
of the different serotypes led to characteristic relationships between the allocated 91 
(best match) serotype and the second-best match. For example, all isolates 92 
assigned as serotype Ia had serotype III as the second-best match. In all cases, the 93 
second-best match was substantially poorer than the best match, demonstrating that 94 
there was no ambiguity in predicted serotype (Figure 1, Table 3). 95 
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The nine discordant and three non-typeable isolates were retested by latex 96 
agglutination (Table 4) and resequenced using the Illumina MiSeq platform, with 97 
sequence processing and WGS-based serotype prediction performed as above. In 98 
all cases, resequencing was consistent with the initial WGS classification. For 6/9 99 
discordant isolates, the new latex agglutination results matched the WGS-based 100 
prediction, suggesting that the initial discordance may have resulted from incorrect 101 
latex agglutination typing or sample mislabelling. The other three initially discordant 102 
isolates, and the three non-typeable isolates, were all classified as non-typeable on 103 
retesting. 104 
This WGS-based method for GBS serotyping, validated using 223 isolates typed 105 
using conventional methods, was therefore highly accurate. Although WGS may not 106 
currently be cost-effective for directly replacing traditional serotyping, costs are likely 107 
to further decrease. Furthermore, WGS may already be the cheapest option for 108 
combined studies, with possibilities to utilise the resulting data for additional 109 
analyses such as multi-locus sequence typing, relatedness to other sequenced 110 
isolates, and detailed phylogenetic analysis. 111 
  112 
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Table 1. Reference sequences used for sequence-based serotype allocation 206 
Serotype Accession Region Reference 
Ia AB028896.2 6982-11695 Yamamoto et al.(20) 
Ib AB050723.1 2264-6880 Watanabe et al.(21) 
II EF990365.1 1915-8221 Martins et al.(22) 
III AF163833.1 6592-11193 Chaffin et al.(23) 
IV AF355776.1 6417-11656 Cieslewicz et al.(24) 
V AF349539.1 6400-12547 Cieslewicz et al.(24) 
VI AF337958.1 6437-10913 Cieslewicz et al.(24) 
VII AY376403.1 3403-8666 Cieslewicz et al.(24)
VIII AY375363.1 2971-7340 Cieslewicz et al.(24) 
IX NA NA This study 
  207 
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Table 2. Serotype allocation by WGS to serotype allocation by latex agglutination  208 
      Serotype allocated by WGS   
    Ia Ib II III IV V VI VII VIII IX Total 
Serotype by 
latex 
agglutination 
Ia 34 0 0 1 0 0 0 0 0 0 35 
Ib 0 9 1 0 0 0 0 0 0 0 10 
II 0 0 25 0 0 0 0 0 0 0 25 
III 3 0 0 111 0 0 0 0 0 1 115 
IV 0 0 0 0 1 0 1 0 0 0 2 
V 0 0 0 0 0 16 0 0 0 0 16 
VI 0 0 0 0 0 1 8 0 0 0 9 
VII 0 0 0 0 0 0 0 5 0 0 5 
VIII 0 0 0 0 0 0 0 0 1* 0 1 
IX 0 1 0 0 0 0 0 0 0 1* 2 
Non-
typeable 
0 1 0 0 0 0 1 1 0 0 3 
  Total 37 11 26 112 1 17 10 6 1 2 223 
*Reference GBS isolates from Statens Serum Institute serotypes VIII and IX 209 
  210 
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Table 3. Relationship between allocated serotype and second-best match (see also Figure 1) 211 
Allocated serotype % match Second-best serotype % match 
Ia 93.91-100 III 64.56 
III 100 Ia 62.98 
V 100 IX 36.26
IX 100 V 31.05 
VI 100 III 26.68 
IV 100 Ia 20.3 
Ib 99.61-100 VI 15.55 
II 99.86-100 IV 9.45
VII 100 Ib 6.95 
VIII 100 none 0 
 212 
  213 
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Table 4. Retyping of discordant and non-typable isolates 214 
  Latex agglutination WGS 
Isolate Reason for 
retyping 
Initial Repeat Initial Repeat 
CB466 Discordant III Ia Ia Ia 
IW8194 Discordant III IX IX IX
IW8466 Discordant Ia III III III 
IW8471 Discordant III Ia Ia Ia 
IW7157 Discordant Ib II II II
SMRU1 Discordant VI V V V 
SMRU25 Discordant IV NT VI VI 
SMRU4 Discordant IX NT Ib Ib 
SMRU59 Discordant III NT Ia Ia 
Z41 Non-typeable NT NT Ib Ib
UK22 Non-typeable NT NT VII VII 
IW2723 Non-typeable NT NT VI VI 
CB454 Control III III III III 
IW4445 Control Ia Ia Ia Ia 
IW4077 Control II II II II 
  215 
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 216 
Figure 1 Discordant isolates show high support for sequence-based serotype allocation. 217 
For each isolate, the percentage of the capsular locus region present (≥95% sequence 218 
identity) for the assigned serotype is shown on the X axis, and that for the serotype showing 219 
the next best match on the Y axis. Isolates showing agreement between sequence-based 220 
and conventional serotyping are shown in grey, those classified as non-typeable by 221 
conventional methods in blue, and discordant isolates in red. Small circles represent single 222 
isolates, the large circle represents 100 isolates. For each serotype, the second-best match is 223 
identical in all cases, leading to the observed horizontal banding (details in Table 3). 224 
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